Buy alert: 50% 3yr revenue CAGR platform at 13x earnings
Second purchase of this incredible 'razor-razorblade' business that currently has no viable competition.
The 22nd pick, 2.5% allocation, was purchased last week for the Sleep Well Portfolio, as planned in the deep dive. Today, we are purchasing the second portion, completing the desired allocation of 5% (and notified in the chat).
The stock rose 50% while I was writing up the report, and has surged 3,000% in the last four years. But now that I understand deeply the potential and the fading risks, I am not hesitating.
You can expect:
high reinvestment opportunities with 50% returns on investments (ROIC)
aligned management with high ownership and excellent execution
mission-critical products to slow to change end-users
unfocused competition and high barriers to entry
squeaky clean balance sheet
low valuation
fading risks
If you are new, read more about us here, and our latest portfolio review here. If you are looking for an above-market return while taking low risk, you can read our Sleep Well Manual to understand our investment process.
Let’s discuss why this European technology platform improves the current Sleep Well Portfolio below. 🎯
